Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Csepregi

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Orvosi Hetilap|June 16, 1996
[H2-receptor antagonists and alcohol: clinical significance]E Nemesánszky, A Csepregi
Orvosi Hetilap|September 8, 1998
[Practical considerations of immunoprophylaxis in viral hepatitis]E Nemesánszky, A Csepregi
Orvosi Hetilap|March 16, 1997
[Cryoglobulinemia in chronic liver diseases: cause or consequence?]A Csepregi, E Nemesánszky
Zeitschrift Fur Gastroenterologie|July 9, 1998
[Cryoglobulinemia and chronic liver diseases]A Csepregi, E Nemesánszky, M Bély
Scandinavian Journal of Immunology|December 11, 2002
Do autoantibodies predict autoimmune liver disease in primary Sjögren's syndrome? Data of 180 patients upon a 5 year follow-upA Csepregi, P Szodoray, M Zeher
Rheumatology International|October 27, 2001
Study of hepatitis C virus infection in 213 Hungarian patients with Sjögren's syndromeP Szodoray, A Csepregi, M Héjjas, et al.
The American Journal of Gastroenterology|March 31, 2001
LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunityA Csepregi, E Nemesánszky, B Luettig, et al.
Orvosi Hetilap|June 1, 2000
[Activity of neutral endopeptidase in serum of patients with primary biliary cirrhosis]K Horvát-Karajz, A Csepregi, E Nemesánszky, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 10, 2007
Low prevalence of Helicobacteraceae in gall-stone disease and gall-bladder carcinoma in the German populationU R M Bohr, D Kuester, F Meyer, et al.
Immunology Letters|June 8, 2000
Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon alpha-2bL Bíró, L Varga, A Pár, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Orvosi Hetilap|June 16, 1996
[H2-receptor antagonists and alcohol: clinical significance]E Nemesánszky, A Csepregi
Orvosi Hetilap|September 8, 1998
[Practical considerations of immunoprophylaxis in viral hepatitis]E Nemesánszky, A Csepregi
Orvosi Hetilap|March 16, 1997
[Cryoglobulinemia in chronic liver diseases: cause or consequence?]A Csepregi, E Nemesánszky
Zeitschrift Fur Gastroenterologie|July 9, 1998
[Cryoglobulinemia and chronic liver diseases]A Csepregi, E Nemesánszky, M Bély
Scandinavian Journal of Immunology|December 11, 2002
Do autoantibodies predict autoimmune liver disease in primary Sjögren's syndrome? Data of 180 patients upon a 5 year follow-upA Csepregi, P Szodoray, M Zeher
Rheumatology International|October 27, 2001
Study of hepatitis C virus infection in 213 Hungarian patients with Sjögren's syndromeP Szodoray, A Csepregi, M Héjjas, et al.
The American Journal of Gastroenterology|March 31, 2001
LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunityA Csepregi, E Nemesánszky, B Luettig, et al.
Orvosi Hetilap|June 1, 2000
[Activity of neutral endopeptidase in serum of patients with primary biliary cirrhosis]K Horvát-Karajz, A Csepregi, E Nemesánszky, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 10, 2007
Low prevalence of Helicobacteraceae in gall-stone disease and gall-bladder carcinoma in the German populationU R M Bohr, D Kuester, F Meyer, et al.
Immunology Letters|June 8, 2000
Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon alpha-2bL Bíró, L Varga, A Pár, et al.
Pageof 2